Literature DB >> 22350660

Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.

Giorgio Treglia1, Paola Castaldi, Guido Rindi, Alessandro Giordano, Vittoria Rufini.   

Abstract

UNLABELLED: Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) are valuable diagnostic tools for patients with neuroendocrine tumours (NETs). To date, a meta-analysis about the diagnostic accuracy of these imaging methods is lacking. Aim of our study is to meta-analyse published data about the diagnostic performance of SMSR PET or PET/CT in patients with thoracic and/or gastroenteropancreatic (GEP) NETs. A comprehensive computer literature search of studies published in PubMed/MEDLINE, Scopus and Embase databases through October 2011 and regarding SMSR PET or PET/CT in patients with NETs was carried out. Only studies in which SMSR PET or PET/CT were performed in patients with thoracic and/or GEP NETs were selected (medullary thyroid tumours and neural crest derived tumours were excluded from the analysis). Pooled sensitivity, pooled specificity and area under the ROC curve were calculated to measure the diagnostic accuracy of SMSR PET and PET/CT in NETs.
RESULTS: Sixteen studies comprising 567 patients were included in this meta-analysis. The pooled sensitivity and specificity of SMSR PET or PET/CT in detecting NETs were 93% (95% confidence interval [95% CI]: 91-95%) and 91% (95% CI: 82-97%), respectively, on a per patient-based analysis. The area under the ROC curve was 0.96. In patients with suspicious thoracic and/or GEP NETs, SMSR PET and PET/CT demonstrated high sensitivity and specificity. These accurate techniques should be considered as first-line diagnostic imaging methods in patients with suspicious thoracic and/or GEP NETs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350660     DOI: 10.1007/s12020-012-9631-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  29 in total

1.  68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Authors:  Thorsten D Poeppel; Ina Binse; Stephan Petersenn; Harald Lahner; Matthias Schott; Gerald Antoch; Wolfgang Brandau; Andreas Bockisch; Christian Boy
Journal:  J Nucl Med       Date:  2011-11-09       Impact factor: 10.057

2.  Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.

Authors:  Tarun Jindal; Arvind Kumar; Balasubramanian Venkitaraman; Roman Dutta; Rakesh Kumar
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

3.  Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study.

Authors:  Annibale Versari; Lorenzo Camellini; Gabriele Carlinfante; Andrea Frasoldati; Franco Nicoli; Elisa Grassi; Carmine Gallo; Francesca P Giunta; Alessandro Fraternali; Diana Salvo; Mattia Asti; Francesco Azzolini; Veronica Iori; Romano Sassatelli
Journal:  Clin Nucl Med       Date:  2010-05       Impact factor: 7.794

4.  Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.

Authors:  Nils F Schreiter; Winfried Brenner; Munenobu Nogami; Ralph Buchert; Alexander Huppertz; Ulrich-Frank Pape; Vikas Prasad; Bernd Hamm; Martin H Maurer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-17       Impact factor: 9.236

Review 5.  Neuroendocrine neoplasms of the gut and pancreas: new insights.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2011-08-02       Impact factor: 43.330

6.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

7.  A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.

Authors:  Irfan Kayani; Brendon G Conry; Ashley M Groves; Thida Win; John Dickson; Martyn Caplin; Jamshed B Bomanji
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

8.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

9.  The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors.

Authors:  Haoping Xu; Min Zhang; Ge Zhai; Miao Zhang; Guang Ning; Biao Li
Journal:  Endocrine       Date:  2009-10-06       Impact factor: 3.633

10.  68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.

Authors:  Valentina Ambrosini; Paolo Castellucci; Domenico Rubello; Cristina Nanni; Alessandra Musto; Vincenzo Allegri; Gian Carlo Montini; Sandro Mattioli; Gaia Grassetto; Adil Al-Nahhas; Roberto Franchi; Stefano Fanti
Journal:  Nucl Med Commun       Date:  2009-04       Impact factor: 1.690

View more
  75 in total

1.  Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.

Authors:  L de la Cueva; P Lloro; M J Sangrós; L López Vélez; P Navarro; L Sarria; S Álvarez; D Abós
Journal:  Clin Transl Oncol       Date:  2017-01-31       Impact factor: 3.405

2.  Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?

Authors:  Kjell Öberg
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

3.  Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

Authors:  Giorgio Treglia; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12       Impact factor: 9.236

Review 4.  PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.

Authors:  Filippo Lococo; Alfredo Cesario; Massimiliano Paci; Angelina Filice; Annibale Versari; Cristian Rapicetta; Tommaso Ricchetti; Giorgio Sgarbi; Marco Alifano; Alberto Cavazza; Giorgio Treglia
Journal:  Tumour Biol       Date:  2014-05-22

Review 5.  Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review.

Authors:  Andrea M Isidori; Emilia Sbardella; Maria Chiara Zatelli; Mara Boschetti; Giovanni Vitale; Annamaria Colao; Rosario Pivonello
Journal:  J Clin Endocrinol Metab       Date:  2015-09       Impact factor: 5.958

6.  Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.

Authors:  Manjunath Goroshi; Tushar Bandgar; Anurag R Lila; Swati Sachin Jadhav; Shruti Khare; Shailesh V Shrikhande; Shinya Uchino; Abhay N Dalvi; Nalini S Shah
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

7.  Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.

Authors:  S Van Binnebeek; B Vanbilloen; K Baete; C Terwinghe; M Koole; F M Mottaghy; P M Clement; L Mortelmans; K Bogaerts; K Haustermans; K Nackaerts; E Van Cutsem; C Verslype; A Verbruggen; C M Deroose
Journal:  Eur Radiol       Date:  2015-07-12       Impact factor: 5.315

8.  Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT.

Authors:  Lino M Sawicki; Cornelius Deuschl; Karsten Beiderwellen; Verena Ruhlmann; Thorsten D Poeppel; Philipp Heusch; Harald Lahner; Dagmar Führer; Andreas Bockisch; Ken Herrmann; Michael Forsting; Gerald Antoch; Lale Umutlu
Journal:  Eur Radiol       Date:  2017-04-24       Impact factor: 5.315

Review 9.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

Authors:  Martijn van Essen; Anders Sundin; Eric P Krenning; Dik J Kwekkeboom
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

10.  Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid.

Authors:  Balasubramanian Venkitaraman; Sellam Karunanithi; Arvind Kumar; G C Khilnani; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.